Filed reports

43 reports · Mar 2016 to Jun 2026

Each report counts once it has at least one extracted financial fact.

Report type	Reports	Facts	Periods
Q1Bundesanzeiger	14	1,335	Mar 2016 to Mar 2026
Half YearBundesanzeiger	11	1,740	Jun 2016 to Jun 2026
Q3Bundesanzeiger	10	1,381	Sep 2016 to Sep 2025
AnnualBundesanzeiger	8	616	Dec 2021 to Dec 2025

Period	Type	Period end	Published	Facts	Source
FY2026 Q2	half year	Jun 30, 2026	Jun 30, 2026	25	Open
FY2026 Q1	q1	Mar 31, 2026	Mar 31, 2026	17	Open
FY2026 Q1	q1	Mar 31, 2026	Mar 31, 2026	82	Open
FY2026 Q1	q1	Mar 31, 2026	Mar 31, 2026	68	Open
FY2025	annual	Dec 31, 2025	Dec 31, 2025	10	Open
FY2025	annual	Dec 31, 2025	Dec 31, 2025	117	Open
FY2025 Q3	q3	Sep 30, 2025	Sep 30, 2025	146	Open
FY2025 Q2	half year	Jun 30, 2025	Jun 30, 2025	225	Open
FY2025 Q1	q1	Mar 31, 2025	Mar 31, 2025	114	Open
FY2024	annual	Dec 31, 2024	Dec 31, 2024	102	Open
FY2024	annual	Dec 31, 2024	Dec 31, 2024	6	Open
FY2024 Q3	q3	Sep 30, 2024	Sep 30, 2024	151	Open

Financial data

298 concepts · 5,072 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Revenue94 · Mar 2016 to Jun 2026
Life Science77 · Mar 2016 to Mar 2026
Operating result (EBIT)²54 · Mar 2016 to Mar 2026
Depreciation & Amortization52 · Mar 2016 to Mar 2026
EBITDA²50 · Mar 2016 to Jun 2025
Investments in intangible assets⁴37 · Mar 2016 to Jun 2025
Business free cash flow35 · Mar 2016 to Sep 2019
EBITDA pre exceptionals (Segment result)34 · Mar 2016 to Jun 2019
Investments in property, plant and equipment⁴34 · Mar 2016 to Jun 2025
Exceptionals22 · Mar 2016 to Sep 2017
Operating Cash Flow22 · Mar 2016 to Jun 2019
EBITDA margin pre exceptionals (% of net sales)20 · Mar 2016 to Sep 2017
EBITDA pre (Segment result)²20 · Mar 2021 to Jun 2026
Performance Materials20 · Mar 2016 to Jun 2019
Adjustments²18 · Mar 2021 to Jun 2025
Liabilities by business sector³17 · Jun 2018 to Jun 2025
Net operating assets¹15 · Mar 2016 to Sep 2017
Intersegment sales13 · Mar 2019 to Jun 2025
Adjustments312 · Jun 2018 to Jun 2019
Impairment losses³11 · Jun 2016 to Jun 2025
Non-cash changes in provisions⁵6 · Mar 2021 to Jun 2025
Reversals of impairment losses6 · Jun 2016 to Mar 2021
Corporate and Other5 · Mar 2021 to Sep 2022
share of Group sales attributable to the Healthcare business sector2 · Sep 2016 to Sep 2017

Adjustments128 · Mar 2021 to Mar 2026
Changes in other assets and liabilities328 · Mar 2021 to Mar 2026
Changes in provisions328 · Mar 2021 to Mar 2026
Changes in working capital128 · Mar 2021 to Mar 2026
Income tax228 · Mar 2021 to Mar 2026
of which: changes in inventories328 · Mar 2021 to Mar 2026
of which: changes in trade accounts receivable328 · Mar 2021 to Mar 2026
Operating result (EBIT)¹27 · Mar 2021 to Mar 2026
Other non-cash income and expenses327 · Mar 2021 to Mar 2026
of which: changes in trade accounts payable/refund liabilities325 · Mar 2021 to Mar 2026
Financial result222 · Mar 2021 to Mar 2026
EBITDA pre¹21 · Sep 2021 to Mar 2026
Neutralization of gains/losses on disposals of fixed assets and other disposals310 · Mar 2021 to Mar 2026
EBITDA²9 · Mar 2021 to Mar 2026
Gross Profit7 · Mar 2017 to Mar 2022
Adjustments (total)¹5 · Mar 2021 to Sep 2022
EBITDA pre margin (in % of net sales)²5 · Jun 2021 to Jun 2024
Gains (+) /losses (–) on the divestment of businesses5 · Mar 2021 to Sep 2022
Integration expenses/IT expenses5 · Mar 2021 to Sep 2022
Other adjustments5 · Mar 2021 to Sep 2022
Restructuring expenses5 · Mar 2021 to Sep 2022
Group research spending ratio4 · Mar 2017 to Mar 2022
Equity ratio3 · Dec 2023 to Dec 2025
Acquisition-related adjustments2 · Mar 2021 to Sep 2022

Business free cash flow9 · Mar 2016 to Jun 2019
Integration costs/IT costs6 · Jun 2016 to Jun 2018
Restructuring costs6 · Jun 2016 to Jun 2018
Acquisition-related exceptionals5 · Jun 2016 to Jun 2018
EBITDA pre exceptionals¹4 · Jun 2017 to Jun 2018
Exceptionals before impairment losses /reversals of impairment losses¹4 · Jun 2017 to Jun 2018
Gains / losses on the divestment of businesses4 · Jun 2016 to Jun 2017
Investments in property, plant and equipment, software as well as advance payments for intangible assets4 · Jun 2017 to Jun 2019
Other exceptionals4 · Jun 2017 to Jun 2018
Changes in trade accounts receivable and receivables from royalties and licenses as reported in the consolidated balance sheet3 · Jun 2018 to Mar 2019
Adjustment first-time consolidation of Sigma-Aldrich2 · Jun 2016
Adjustments in EBITDA2 · Mar 2024 to Mar 2026
Changes in inventories as reported in the consolidated balance sheet2 · Jun 2018 to Mar 2019
EBITDA²2 · Jun 2018
Exceptionals (total)¹2 · Jun 2017
Impairment losses2 · Jun 2018
Adjustments first-time consolidation of Sigma-Aldrich1 · Sep 2016
Lease payments31 · Mar 2019

684 facts

Figures broken down by business line, region, product or another axis the company reports on.

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

32 calls · May 2018 to Aug 2026

Transcripts with management claims and analyst questions, one per fiscal period.

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.